Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Arbutus Biopharma Corporation - Common Stock
(NQ:
ABUS
)
4.540
+0.060 (+1.34%)
Streaming Delayed Price
Updated: 11:01 AM EDT, Apr 16, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
408,348
Open
4.470
Bid (Size)
4.530 (1,700)
Ask (Size)
4.540 (3,200)
Prev. Close
4.480
Today's Range
4.435 - 4.555
52wk Range
2.940 - 5.100
Shares Outstanding
99,161,234
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B
April 15, 2026
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
March 23, 2026
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Performance
YTD
-4.8%
-4.8%
1 Month
+4.1%
+4.1%
3 Month
-5.0%
-5.0%
6 Month
+1.6%
+1.6%
1 Year
+43.7%
+43.7%
More News
Read More
Moderna Settles High-Stakes LNP Patent War with $2.25 Billion Agreement
March 05, 2026
Via
MarketMinute
Topics
Intellectual Property
Lawsuit
Moderna-Arbutus-Genevant Patent Settlement: Wall Street Says Not Best-Case Scenario But Removes Overhang For MRNA Stock
↗
March 04, 2026
Via
Stocktwits
Topics
Intellectual Property
ABUS Stock On Track For Biggest Intraday Drop In Over 5 Years – What’s The Issue Around Its Patent In Europe?
↗
January 16, 2026
Via
Stocktwits
Topics
Intellectual Property
MRNA Shares Rally After Hours On Inking Settlement Deal Over Vaccine Patent Row
↗
March 03, 2026
Via
Stocktwits
Topics
Intellectual Property
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
March 03, 2026
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna
March 03, 2026
From
Roivant Sciences
Via
GlobeNewswire
The mRNA 2.0 Inflection: A Deep Dive into Moderna (MRNA) as it Faces a Critical 2026
January 16, 2026
Via
Finterra
Topics
Initial Public Offering
Intellectual Property
Lawsuit
Get insights into the top gainers and losers of Friday's pre-market session.
↗
January 16, 2026
Via
Chartmill
Moderna’s High-Stakes Transformation: Navigating the Post-Pandemic Pivot
January 14, 2026
Via
Finterra
Topics
Initial Public Offering
Intellectual Property
The mRNA Pivot: Moderna Navigates Regulatory Headwinds and Tariff Turmoil in a Volatile 2026 Biotech Landscape
January 12, 2026
Via
MarketMinute
Topics
Economy
Intellectual Property
World Trade
Moderna’s Second Act: A 2026 Deep Dive into the Future of mRNA Therapeutics
January 09, 2026
Via
PredictStreet
Topics
Initial Public Offering
Intellectual Property
Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 13, 2025
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Biopharma (NASDAQ:ABUS) Shows Strong Technical and Fundamental Momentum
↗
October 21, 2025
Via
Chartmill
Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025
October 07, 2025
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus (ABUS) Q2 Revenue Surges 529%
↗
August 06, 2025
Via
The Motley Fool
Topics
Intellectual Property
Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 06, 2025
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus
June 25, 2025
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 14, 2025
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025
May 07, 2025
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025
April 23, 2025
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
March 27, 2025
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
March 03, 2025
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO
February 25, 2025
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Frequently Asked Questions
Is Arbutus Biopharma Corporation - Common Stock publicly traded?
Yes, Arbutus Biopharma Corporation - Common Stock is publicly traded.
What exchange does Arbutus Biopharma Corporation - Common Stock trade on?
Arbutus Biopharma Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Arbutus Biopharma Corporation - Common Stock?
The ticker symbol for Arbutus Biopharma Corporation - Common Stock is ABUS on the Nasdaq Stock Market
What is the current price of Arbutus Biopharma Corporation - Common Stock?
The current price of Arbutus Biopharma Corporation - Common Stock is 4.540
When was Arbutus Biopharma Corporation - Common Stock last traded?
The last trade of Arbutus Biopharma Corporation - Common Stock was at 04/16/26 11:01 AM ET
What is the market capitalization of Arbutus Biopharma Corporation - Common Stock?
The market capitalization of Arbutus Biopharma Corporation - Common Stock is 450.19M
How many shares of Arbutus Biopharma Corporation - Common Stock are outstanding?
Arbutus Biopharma Corporation - Common Stock has 450M shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
